تقرير
أعرض في EDS

Sepsis Due to Achromobacter xylosoxidans in a Tertiary Care Centre: Case Series.

التفاصيل البيبلوغرافية
العنوان: Sepsis Due to Achromobacter xylosoxidans in a Tertiary Care Centre: Case Series.
المؤلفون: Mudey G; Department of Microbiology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND., Kunjalwar R; Department of Microbiology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND., Sahu G; Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND., Mahajan SM; Department of Microbiology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND., Meshram S; Department of Microbiology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
المصدر: Cureus [Cureus] 2023 Jul 17; Vol. 15 (7), pp. e42052. Date of Electronic Publication: 2023 Jul 17 (Print Publication: 2023).
نوع المنشور: Case Reports
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Achromobacter xylosoxidans , also known as  Alcaligenes xylosoxidans , is a low-virulence, non-fermenter gram-negative bacillus mainly found in marine environments. We report a detailed series of four high-risk cases of septicemia with the common variable of positive blood cultures for A. xylosoxidans . All four blood isolates were multi-drug resistant and susceptible to meropenem and trimethoprim-sulfamethoxazole. Two patients responded well to the treatment with meropenem and trimethoprim-sulfamethoxazole and two patients died. It should never be assumed that Achromobacter is a contaminant even though it is relatively infrequently isolated from clinical samples. This infection can progress to fatal bacteremia, even in otherwise healthy people, and it can potentially cause severe conditions in premature infants. With only a limited number of antibiotics demonstrating bactericidal properties, the possibility of failure in empirical treatment is significant. As a result, it is important to have a precise comprehension of this uncommon yet deadly illness in order to increase the probability of successful treatment.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2023, Mudey et al.)
References: Braz J Infect Dis. 2013 Jul-Aug;17(4):450-4. (PMID: 23742802)
J Clin Microbiol. 2006 Sep;44(9):3415-7. (PMID: 16954289)
Cureus. 2022 Jun 17;14(6):e26048. (PMID: 35747118)
J Infect Dev Ctries. 2011 Mar 02;5(2):138-41. (PMID: 21389595)
Respir Med Case Rep. 2018 Oct 16;25:311-313. (PMID: 30386722)
Int J Antimicrob Agents. 2010 Jan;35(1):68-71. (PMID: 19889520)
J Lab Physicians. 2015 Jul-Dec;7(2):124-7. (PMID: 26417165)
Eur J Clin Microbiol Infect Dis. 2003 Jun;22(6):360-3. (PMID: 12750959)
فهرسة مساهمة: Keywords: achromobacter xylosoxidans; bacteremia; gram-negative organism; immunocompromised patient; multi-drug resistant
تواريخ الأحداث: Date Created: 20230821 Latest Revision: 20230823
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10434726
DOI: 10.7759/cureus.42052
PMID: 37602012
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.42052